Wire · opportunities
Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 24 October 2026 · Fusion42 review
Novartis' oral Bruton tyrosine kinase inhibitor remibrutinib significantly reduced relapse rates and disability progression versus teriflunomide in two global Phase 3 trials in adults with relapsing multiple sclerosis, with a favourable safety profile. Novartis plans to seek regulatory approval worldwide based on these results.
This Wire brief sits within Fusion42's coverage of Medtech, and 2 sources have reported it between 24 Oct 2026 and 26 Oct 2026.
◆ ◆ The Wire takeaway
You must prepare for remibrutinib entering relapsing MS markets as it offers a new oral treatment that reduces relapses and disability at a competitive rate. Clinical teams and patient access strategies should now align with its likely global regulatory launch.
◆ Coverage
2 sources · first reported 24 Oct 2026 · latest 26 Oct 2026
◆ Related on Wire
◆ Topics